Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

BARDA Rejects Maxygen’s Proposal to Develop MAXY-G34 for Acute Radiation Syndrome

BARDA cited issues like reliance on overseas manufacturing, dependence on subcontractors, and IP uncertainty.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »